Mersana Therapeutics shares are trading lower after the company announced that the UPLIFT clinical trial of upifitamab rilsodotin did not meet its primary endpoint.
Portfolio Pulse from Benzinga Newsdesk
Mersana Therapeutics announced that the UPLIFT clinical trial of upifitamab rilsodotin did not meet its primary endpoint, causing its shares to trade lower.

July 27, 2023 | 7:28 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Mersana Therapeutics' stock is trading lower due to the failure of the UPLIFT clinical trial to meet its primary endpoint.
The failure of a clinical trial often leads to a decrease in the stock price of a pharmaceutical company. In this case, Mersana Therapeutics' UPLIFT clinical trial did not meet its primary endpoint, which is likely causing investors to lose confidence in the company's ability to bring the drug to market, leading to a decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100